Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
J Oncol Pharm Pract. 2019 Apr;25(3):551-557. doi: 10.1177/1078155217745144. Epub 2017 Dec 5.
J Oncol Pharm Pract. 2019.
PMID: 29207939